{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:29:41Z","timestamp":1784676581208,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003962.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000}}],"reference-count":362,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003962.pub3","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T12:20:07Z","timestamp":1706790007000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Non-immunosuppressive treatment for IgA nephropathy"],"prefix":"10.1002","volume":"2024","author":[{"given":"David J","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Reid","sequence":"additional","affiliation":[{"name":"Central Clinical School, Faculty of Medicine and Health; University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"},{"name":"College of Medicine and Public Health; Flinders University; Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Samuels","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology and Hypertension; UT-Houston Health Science Center; Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A","family":"Molony","sequence":"additional","affiliation":[{"name":"Internal Medicine; UT-Houston Health Science Center; Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"},{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"17","key":"10.1002\/14651858.CD003962.pub3-BIB0001|cit1","first-page":"524","article-title":"The effect of diphenylhydantoin on IgA nephropathy","volume":"128","author":"Adamkova","year":"1989","journal-title":"Casopis Lekaru Ceskych"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0002|cit2","first-page":"89A","article-title":"The effect of fish oil in patients with IgA nephropathy and renal function impairment: a prospective study [abstract no: A0468]","volume":"12","author":"Alexopoulos","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1081\/JDI-200026763","article-title":"Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a \"very low dose\" regimen","volume":"26","author":"Alexopoulos","year":"2004","journal-title":"Renal Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0004|cit4","first-page":"28","article-title":"Treatment of severe IgAN with omega-3 fatty acids: the effect of a \"very lose dose\" regime [abstract no: O92]","volume":"17","author":"Alexopoulos","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0005|cit5","first-page":"A63","article-title":"The effect of fish-oil in the treatment of IGA nephropathy (IGAN) [abstract]","volume":"16","author":"Stangou","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0006|cit6","first-page":"115A","article-title":"The effect of fish-oil in human IgA nephropathy (IgAN) [abstract no: A0591]","volume":"10","author":"Stangou","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0007|cit7","first-page":"346","article-title":"Effect of combination therapy of captopril and dipyridamole on proteinuria in patients with IgA nephropathy [abstract]","volume":"5","author":"Bang","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3349\/ymj.2011.52.4.588","article-title":"Anti-proteinuric effect of sulodexide in immunoglobulin A nephropathy","volume":"52","author":"Bang","year":"2011","journal-title":"Yonsei Medical Journal"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0009|cit9","unstructured":"Bang K Lee YS Kim M Kang JH Chin HJ Joo KW Anti-proteinuric effect of sulodexide in biopsy-proven IgA nephropathy [abstract no: SA278] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0010|cit10","first-page":"152A","article-title":"A randomized study of sulodexide therapy for the treatment of biopsy-proven IgA nephropathy [abstract no: TH-PO186]","volume":"20","author":"Bang","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000423895","article-title":"Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy","volume":"111","author":"Bannister","year":"1995","journal-title":"Contributions to Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0012|cit12","first-page":"S128","article-title":"Effect of nifedipine and enalapril on the progression of IgA glomerulonephritis (IgA GN) [abstract no: P214]","volume":"3","author":"Bannister","year":"1997","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0013|cit13","first-page":"128","article-title":"Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial","volume":"31","author":"Bennett","year":"1989","journal-title":"Clinical Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0014|cit14","first-page":"729","article-title":"Clinical study on Shenning Mixture in treating IgA nephropathy","volume":"20","author":"Bo","year":"2000","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1067\/mcp.2000.105330","article-title":"Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy","volume":"67","author":"Buemi","year":"2000","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000186370","article-title":"Effects of dipyridamole on the short-term evolution of glomerulonephritis","volume":"58","author":"Camara","year":"1991","journal-title":"Nephron"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0017|cit17","first-page":"240A","article-title":"Effects of candesartan on clinical remission in IgA nephropathy treated with steroid pulse therapy and tonsilectomy (CAST IgA Study) - a randomized control study [abstract no: TH-PO661]","volume":"26","author":"Kohagura","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1159\/000489914","article-title":"Add-on effect of angiotensin receptor blockade (candesartan) on clinical remission in active IgA nephropathy patients treated with steroid pulse therapy and tonsillectomy: a randomized, parallel-group comparison trial","volume":"43","author":"Kohagura","year":"2018","journal-title":"Kidney & Blood Pressure Research"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0272-6386(87)80145-2","article-title":"Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis","volume":"9","author":"Chan","year":"1987","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00467-003-1205-2","article-title":"Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study","volume":"18","author":"Chan","year":"2003","journal-title":"Pediatric Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0021|cit21","first-page":"67A","article-title":"The effect of long-term urokinase treatment combined with angiotensin-converting enzyme inhibitor on IgA nephropathy with glomerular sclerosis: a clinical control study [abstract no: A0354]","volume":"12","author":"Chen","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/ndt\/gfh069","article-title":"Effects of co-administration of urokinase and benazepril on severe IgA nephropathy","volume":"19","author":"Chen","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003962.pub3-BIB0023|cit23","first-page":"1061","article-title":"Prospective, multi-centered, randomized and controlled trial on effect of Shenle Capsule in treating patients with IgA nephropathy of Fei-Pi qi-deficiency syndrome","volume":"26","author":"Chen","year":"2006","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine]"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0024|cit24","first-page":"101","article-title":"Multicentered, randomized, controlled clinical trial on patients with IgA nephropathy of Qi-yin deficiency syndrome type","volume":"27","author":"Chen","year":"2007","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine]"},{"issue":"1-2","key":"10.1002\/14651858.CD003962.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1797.1998.tb00316.x","article-title":"A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy","volume":"4","author":"Cheng","year":"1998","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0026|cit26","unstructured":"Cheng IK Fang GX Wong MC Ji YL Yeung H A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract] 12th International Congress of Nephrology; 1993 June 13-18; Jerusalem, Israel 1993 45"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/nep.12359","article-title":"Valsartan combined with clopidogrel and\/or leflunomide for the treatment of progressive immunoglobulin A nephropathy","volume":"20","author":"Cheng","year":"2015","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0028|cit28","first-page":"215","article-title":"Controlled trial of phenytoin therapy in IgA nephropathy","volume":"13","author":"Clarkson","year":"1980","journal-title":"Clinical Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1445-5994.1980.tb03487.x","article-title":"Controlled trial of phenytoin therapy in IgA nephropathy [abstract]","volume":"10","author":"Clarkson","year":"1980","journal-title":"Australian & New Zealand Journal of Medicine"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003962.pub3-BIB0030|cit30","first-page":"iv295","article-title":"Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in IgA nephropathy: promising results on proteinuria at six months [abstract no: MO021]","volume":"21","author":"Costanzi","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ndt\/gfn454","article-title":"Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial","volume":"24","author":"Ferraro","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"18","key":"10.1002\/14651858.CD003962.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199411033311804","article-title":"A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group","volume":"331","author":"Bergstralh","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD003962.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1681\/ASN.V1081772","article-title":"The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group","volume":"10","author":"Grande","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0034|cit34","unstructured":"Holub BJ Bergstralh EJ Effects of omega-3 fatty acids in IgA nephropathy: maintenance of lower proportions of n-6 eicosanoid precursors in plasma phospholipids in response to fish oil preserves renal function [abstract] 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 64"},{"issue":"7","key":"10.1002\/14651858.CD003962.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/ndt\/17.7.1197","article-title":"Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy","volume":"17","author":"Donadio","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0036|cit36","first-page":"65","article-title":"Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group","volume":"41","author":"Donadio","year":"1994","journal-title":"Clinical Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0037|cit37","first-page":"829","article-title":"A controlled trial of fish oil in IGA nephropathy (IGAN) [abstract]","volume":"5","author":"Donadio","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0038|cit38","first-page":"145A","article-title":"The long-term outcome of patients with IgA nephropathy (IgAN) treated with fish oil in a placebo-controlled, randomized clinical trial [abstract no: M1061]","volume":"9","author":"Donadio","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0039|cit39","first-page":"831","article-title":"Morphology assessment does not correlate with subsequent change in renal function in IgA nephropathy (IgA) [abstract no: 107P]","volume":"5","author":"Heilman","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.V124791","article-title":"A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy","volume":"12","author":"Larson","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0041|cit41","first-page":"675A","article-title":"Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids (w-3 PUFA) in the treatment of patients with IgA nephropathy [abstract no: SA-PO471]","volume":"17","author":"Donadio","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2215\/CJN.00260106","article-title":"Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?","volume":"1","author":"Donadio","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"7","key":"10.1002\/14651858.CD003962.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/ndt\/17.7.1197","article-title":"Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy","volume":"17","author":"Donadio","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD003962.pub3-BIB0044|cit44","first-page":"10A","article-title":"Angiotensin-converting enzyme (ACE) genotype influences renal outcome in high-risk patients with IgA nephropathy (IgAN) treated with omega-3 fatty acids (n-3 FA) [abstract no: F-FC045]","volume":"15","author":"Donadio","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD003962.pub3-BIB0045|cit45","first-page":"59A","article-title":"High-dose versus low-dose omega-3 fatty acids in patients with severe IgA nephropathy (IgAN): a randomized trial [abstract no: A0320]","volume":"11","author":"Donadio","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0046|cit46","first-page":"968","article-title":"A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]","volume":"10","author":"Frasca","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-199713040-00002","article-title":"Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis","volume":"13","author":"Frasca","year":"1997","journal-title":"Clinical Drug Investigation"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oxfordjournals.ndt.a027280","article-title":"Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function","volume":"11","author":"Frasca","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3736\/jcim20050509","article-title":"Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan","volume":"3","author":"Guan","year":"2005","journal-title":"Zhong Xi Yi Jie He Xue Bao [Journal of Chinese Integrative Medicine]"},{"issue":"8","key":"10.1002\/14651858.CD003962.pub3-BIB0050|cit50","first-page":"841","article-title":"Effect of treatment of non-nephrotic syndrome IgA nephropathy with Shenyanning","volume":"30","author":"Guo","year":"2010","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine]"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0051|cit51","first-page":"149A","article-title":"A randomized, prospective, controlled study of effect of angiotensin-converting enzyme inhibition on proteinuria and renal function in IGA nephropathy [abstract no: A0765]","volume":"9","author":"Hashizume","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"Oct","key":"10.1002\/14651858.CD003962.pub3-BIB0053|cit53","first-page":"352A","article-title":"Hong Kong study using Valsartan in IgA nephropathy (HKVIN) - a double-blind randomized placebo-controlled study [abstract no: SA-PO238]","volume":"15","author":"Li","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003962.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1291\/hypres.27.963","article-title":"Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy","volume":"27","author":"Horita","year":"2004","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0055|cit55","first-page":"A37","article-title":"Aldosterone breakthrough during combined angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in patients with IgA nephropathy [abstract no: M-P020083]","volume":"10","author":"Horita","year":"2005","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/08860220701260511","article-title":"Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy","volume":"29","author":"Horita","year":"2007","journal-title":"Renal Failure"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003962.pub3-BIB0058|cit58","first-page":"iv332","article-title":"Effects of co-administration of prednisolone plus losartan in moderate proteinuric IgA nephropathy [abstract no: MP099]","volume":"21","author":"Horita","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD003962.pub3-BIB0059|cit59","first-page":"967","article-title":"Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study","volume":"35","author":"Hotta","year":"1993","journal-title":"Japanese Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0060|cit60","first-page":"211","article-title":"Phenytoin in treatment of Berger's Disease","volume":"37","author":"Houssin","year":"1984","journal-title":"Ouest Medical"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0061|cit61","first-page":"1518","article-title":"Advanced oxidation protein products (AOPP) and degalactosylated IgA1 in patients with IgA nephropathy (IgA N): a prospective double blind randomized placebo controlled trial with ACE inhibitors [abstract no: COD. OP 48]","volume":"21","author":"Amore","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0062|cit62","first-page":"447","article-title":"Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial","volume":"14","author":"Coppo","year":"2001","journal-title":"Journal of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003962.pub3-BIB0063|cit63","first-page":"818A","article-title":"Follow-up analysis of patients who reached the end-point during the IgACE, a placebo-controlled trial of ACE-inhibitors in children and young people with IgA nephropathy and moderate proteinuria [abstract no: SU-PO1050]","volume":"18","author":"Coppo","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0064|cit64","first-page":"1510","article-title":"IgACE: first multicentric prospective double blind randomized and placebo controlled study on ACE-inhibitors (ACE-I) administration in moderately proteinuric IgA nephropathy (IgAN) in the young [abstract no: MO018]","volume":"21","author":"Coppo","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"Coppo","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003962.pub3-BIB0066|cit66","first-page":"iv294","article-title":"IgACE: first multicentric prospective double blind randomized and placebo controlled study on ace-inhibitors (ACE-I) administration in moderately proteinuric IgA nephropathy (IgAN) in the young [abstract no: MO018]","volume":"21","author":"Coppo","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0067|cit67","first-page":"553","article-title":"IgACE: first prospective double-blind randomized placebo-controlled multicenter trial of ACE-inhibitors (ACE-I) in moderately proteinuric IgA nephropathy (IgAN) in the young [abstract no: F-PO995]","volume":"16","author":"Coppo","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0068|cit68","unstructured":"Coppo R IgACE-BIOMED multicenter study on treatment of IgAN with ACE-I European Society for Paediatric Nephrology 2002"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003962.pub3-BIB0069|cit69","first-page":"iv383","article-title":"Advanced oxidation protein products (AOPP) and degalactosylated IgA1 in patients with IgA nephropathy (IgAN): a prospective double blind randomized placebo controlled trial with ACE inhibitors [abstract no: MP251]","volume":"21","author":"Mancuso","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD003962.pub3-BIB0070|cit70","first-page":"vi113","article-title":"Systemic microinflammation in IgA nephropathy: down-modulation by ACE-inhibitors observed in a placebo-controlled trial [abstract no: FP285]","volume":"22","author":"Mancuso","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0071|cit71","first-page":"567A","article-title":"ACE-inhibition (ACE-I) down modulates a microinflammatory syndrome detectable in patients with proteinuric IgA nephropathy (IgAN) during a prospective double blind trial [abstract no: TH-F-DS1094]","volume":"17","author":"Mancuso","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0072|cit72","first-page":"422","article-title":"Advanced oxidation protein products (AOPP) and a degalactosylated IgA1 in patients with IgA nephropathy (IgAN) during a prospective, double blind, placebo controlled trial of ACE-inhibitors [abstract no: F-PO405]","volume":"16","author":"Peruzzi","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0073|cit73","unstructured":"Peruzzi L Coppo R Amore A Camilla R IgACE TG Time average proteinuria, urinary MCP-1\/EGF and IL-6\/EGF as predictors of unfavourable outcome in the IgACE trial [abstract no: SU298] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003962.pub3-BIB0074|cit74","first-page":"819A","article-title":"ACE gene insertion\/deletion (I\/D) polymorphism and ACE-inhibitors (ACE-I) response in the IgACE trial [abstract no: SU-PO1053]","volume":"18","author":"Peruzzi","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0075|cit75","first-page":"1625","article-title":"Proteinuria as early predictor of final outcome in IgACE, a placebo controlled trial of ACE-inhibitors in children and young people with IgA nephropathy and moderate proteinuria [abstract no: P116]","volume":"23","author":"Peruzzi","year":"2008","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003962.pub3-BIB0076|cit76","first-page":"552A","article-title":"Proteinuria as early predictor of final outcome in IgACE trial [abstract no: F-PO1952]","volume":"19","author":"Peruzzi","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0077|cit77","first-page":"1625","article-title":"Follow-up analysis of patients who reached the end-point during the IgACE, a placebo controlled trial of ACE-inhibitors in children and young adult people with IgA nephropathy and moderate proteinuria [abstract no: P114]","volume":"23","author":"Peruzzi","year":"2008","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003962.pub3-BIB0078|cit78","first-page":"iv295","article-title":"Urinary cytokines and chemokines excretion (IL-6\/EGF, MCP-1\/EGF) in patients with IgA nephropathy (IgAN) during a prospective double blind trial with ACE-inhibitors [abstract no: MO023]","volume":"21","author":"Peruzzi","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0079|cit79","first-page":"553A","article-title":"Urinary IL-6\/EGF and MCP-1\/EGF ratio in patients with IgA nephropathy (IgAN) during a prospective, double blind, placebo controlled trial of ACE-inhibitors [abstract no: F-PO994]","volume":"16","author":"Roasio","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10157-003-0241-3","article-title":"Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study","volume":"7","author":"Iino","year":"2003","journal-title":"Clinical & Experimental Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1291\/hypres.27.21","article-title":"Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study","volume":"27","author":"Iino","year":"2004","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003962.pub3-BIB0082|cit82","first-page":"363","article-title":"Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension: a report from Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) [abstract no: T58]","volume":"18","author":"Iino","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD003962.pub3-BIB0083|cit83","first-page":"785A","article-title":"Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension; a report from Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT study) [abstract no: PU056]","volume":"14","author":"Iino","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD003962.pub3-BIB0084|cit84","first-page":"753A","article-title":"Renoprotective effect of losartan in comparison to amlodipine in hypertensive patients with advanced IgA nephropathy [abstract no: SU-PO988]","volume":"14","author":"Kawamura","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3904\/kjim.2014.266","article-title":"Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial","volume":"31","author":"Jo","year":"2016","journal-title":"Korean Journal of Internal Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0086|cit86","first-page":"633A","article-title":"A randomized multicenter trial of valsartan in normotensive IgA nephropathy with mild proteinuria [abstract no: SAPO3385)","volume":"11","author":"Jo","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0087|cit87","first-page":"74A","article-title":"Tubulointerstitial fibrosis (TIF) predicts renal protective effects of ACE inhibitor in IgA nephropathy [abstract no: A0389]","volume":"12","author":"Kanno","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/qjmed\/hci036","article-title":"Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation","volume":"98","author":"Kanno","year":"2005","journal-title":"Qjm"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003962.pub3-BIB0089|cit89","first-page":"524","article-title":"Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IGA nephropathy with mild histological findings and moderate proteinuria [abstract no: T756]","volume":"18","author":"Kano","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5414\/CNP60085","article-title":"Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria","volume":"60","author":"Kano","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD003962.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00467-006-0272-6","article-title":"Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy","volume":"21","author":"Kawasaki","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0092|cit92","first-page":"544A","article-title":"The beneficial effects of body weight reduction in overweight patients with proteinuric immunoglobulin A nephropathy: a randomized controlled trial [abstract no: FR-PO787]","volume":"24","author":"Kittiskulnam","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.jrn.2014.01.016","article-title":"The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin A nephropathy: a randomized controlled trial","volume":"24","author":"Kittiskulnam","year":"2014","journal-title":"Journal of Renal Nutrition"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0094|cit94","unstructured":"Lee G Choong HL Chian GSC Woo KT Stabilisation of elevated serum creatinine (CR) in dipyridamole (DYP) and warfarin (WAR) treated patients with IgA nephropathy (IGAN): a three year controlled trial [abstract] 9th Asian Colloquium in Nephrology; 1992 May 17-21; Seoul, Korea 1992 106"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1440-1797.1997.tb00201.x","article-title":"Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment","volume":"3","author":"Lee","year":"1997","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0096|cit96","first-page":"276","article-title":"Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment [abstract]","volume":"31","author":"Lee","year":"1989","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0097|cit97","first-page":"504","article-title":"Effects of Astragalus injection on renal tubular function in patients with IgA nephropathy","volume":"26","author":"Li","year":"2006","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine]"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3736\/jcim20080306","article-title":"Efficacy of hirudin in treating immunoglobulin A nephropathy with hematuria: a randomized controlled trial","volume":"6","author":"Li","year":"2008","journal-title":"Zhong Xi Yi Jie He Xue Bao [Journal of Chinese Integrative Medicine]"},{"issue":"12","key":"10.1002\/14651858.CD003962.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jfma.2013.10.019","article-title":"Huai Qi Huang ameliorates proteinuria and hematuria in mild IgA nephropathy patients: a prospective randomized controlled study","volume":"112","author":"Li","year":"2013","journal-title":"Journal of the Formosan Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.amjmed.2012.06.028","article-title":"Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor","volume":"126","author":"Li","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0101|cit101","first-page":"437","article-title":"Comparison of therapeutic effect of higher-dose valsartan combined with higher dose of lotensin for IgA nephropathy","volume":"28","author":"Liu","year":"2007","journal-title":"Journal of Xi'an Jiaotong University (Medical Sciences)"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0102|cit102","first-page":"12A","article-title":"Oral calcitriol for reduction of proteinuria in patients with igA nephropathy: a randomized, controlled trial [abstract no: TH-OR049]","volume":"22","author":"Liu","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.ajkd.2011.09.014","article-title":"Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial","volume":"59","author":"Liu","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3892\/etm.2016.3312","article-title":"Clinical effects of perazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules for treatment of children with IgA nephropathy","volume":"12","author":"Liu","year":"2016","journal-title":"Experimental & Therapeutic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003962.pub3-BIB0106|cit106","first-page":"ii1029","article-title":"Change of proteinuria after adding spironolactone ACE inhibitor or angiotensin receptor blockers in IGA nephropathy, a pilot study [abstract no: SA309]","volume":"2","author":"Lv","year":"2009","journal-title":"NDT Plus"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0107|cit107","first-page":"265","article-title":"ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study","volume":"9","author":"Maschio","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0108|cit108","first-page":"658","article-title":"ACE inhibition reduced proteinuria in normotensive patients with IgA nephropathy (IGAN) [abstract]","volume":"3","author":"Maschio","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD003962.pub3-BIB0109|cit109","first-page":"337A","article-title":"Omega-3 fatty acids (O3FA) for patients with IgA nephropathy (IgAN): Efficacy is dose-dependent. Report from the North American (NA) IgAN trial [abstract no: SA-PO171]","volume":"15","author":"Hogg","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2215\/CJN.02300606","article-title":"Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2215\/CJN.01020905","article-title":"Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with ig a nephropathy: report from the Southwest Pediatric Nephrology Study Group","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0112|cit112","first-page":"C64","article-title":"Clinical trial of alternate-day prednisone or daily omega-3 fatty acids in patients with IgA nephropathy [abstract no: OFC10]","volume":"19","author":"Hogg","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD003962.pub3-BIB0113|cit113","first-page":"751A","article-title":"Multicenter, placebo-controlled trial of alternate-day prednisone (QOD-PRED) or daily omega-3 fatty acids (OM-3 FA) in children and young adults with IgA nephropathy (IgAN). Report from the Southwest Pediatric Nephrology Study Group [abstract no: SU-PO979]","volume":"14","author":"Hogg","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0272-6386(95)90445-X","article-title":"A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study","volume":"26","author":"Hogg","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000013619","article-title":"Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy","volume":"20","author":"Nakamura","year":"2000","journal-title":"American Journal of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD003962.pub3-BIB0116|cit116","first-page":"1195","article-title":"Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy","volume":"20","author":"Nakamura","year":"2007","journal-title":"American Journal of Hypertension"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0117|cit117","first-page":"488A","article-title":"Antiproteinuric effect on the combination therapy of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker is synergetic in IgA nephropathy [abstract no: A2523]","volume":"12","author":"Nakao","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0118|cit118","first-page":"A94","article-title":"Different antiproteinuric mechanisms of converting enzyme inhibitor and losartan in hypertensive patients with IgA nephropathy [abstract]","volume":"15","author":"Panichi","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0119|cit119","first-page":"44","article-title":"Effects of losartan and amlodipine on proteinuria and urinary tgf-b1 excretion in patients with IgA nephropathy [abstract no: O148]","volume":"17","author":"Park","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/gfg090","article-title":"Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy","volume":"18","author":"Park","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003962.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1681\/ASN.V9122308","article-title":"The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin","volume":"9","author":"Perico","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0122|cit122","first-page":"96A","article-title":"The antiproteinuric effect of angiotensin antagonists in human IgA nephropathy is potentiated by indomethacin [abstract no: S160]","volume":"9","author":"Perico","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0123|cit123","first-page":"F457","article-title":"ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy","volume":"276","author":"Remuzzi","year":"1999","journal-title":"American Journal of Physiology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0124|cit124","first-page":"183","article-title":"Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study","volume":"41","author":"Pettersson","year":"1994","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0126|cit126","unstructured":"Qian JQ He Y Hu P Zhang Q Treatment of IgA nephropathy with Tripterygium Wilfordii glycoside [abstract] 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK 1987 87"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0127|cit127","first-page":"A52","article-title":"Effects of short-term administration of an angiotensin receptor antagonist, and angiotensin converting enzyme inhibitor and a nitric oxide donor on renal hemodynamics, proteinuria and nitric oxide levels [abstract]","volume":"12","author":"Roccatello","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0128|cit128","first-page":"S129","article-title":"Effects of short-term administration of an angiotensin receptor antagonist, an angiotensin converting enzyme inhibitor and a nitric oxide donor on renal hemodynamics, proteinuria and nitric oxide blood levels [abstract no: P218]","volume":"3","author":"Roccatello","year":"1997","journal-title":"Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003962.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ndt\/15.7.988","article-title":"Effects of angiotensin II blockade on nitric oxide blood levels in IgA nephropathy","volume":"15","author":"Roccatello","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0130|cit130","first-page":"A36","article-title":"The effect of fish oil on serum interleukin levels in IgA nephropathy [abstract no: PS2-12]","volume":"8","author":"Ross","year":"2003","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/ajkd.2001.25176","article-title":"Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy","volume":"38","author":"Russo","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0272-6386(12)80511-7","article-title":"Sodium cromoglycate therapy in IgA nephropathy: a preliminary short-term trial","volume":"15","author":"Sato","year":"1990","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0133|cit133","first-page":"399","article-title":"The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors","volume":"41","author":"Shi","year":"2002","journal-title":"Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine]"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000331453","article-title":"Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial","volume":"35","author":"Shi","year":"2012","journal-title":"Kidney & Blood Pressure Research"},{"issue":"11","key":"10.1002\/14651858.CD003962.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00467-018-4011-6","article-title":"Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT","volume":"33","author":"Shima","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00467-018-4099-8","article-title":"Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study)","volume":"34","author":"Shima","year":"2019","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1291\/hypres.31.1711","article-title":"Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy","volume":"31","author":"Shimizu","year":"2008","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5414\/CNP60318","article-title":"The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy","volume":"60","author":"Song","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"e62736","DOI":"10.1371\/journal.pone.0062736","article-title":"The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study","volume":"8","author":"Szeto","year":"2013","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0140|cit140","first-page":"372","article-title":"Losartan and enalapril in IgA nephropathy [abstract no: A1879]","volume":"10","author":"Tesar","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0141|cit141","first-page":"A64","article-title":"Losartan and enalapril in IgA nephropathy [abstract]","volume":"14","author":"Tesar","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0254-6272(13)60102-8","article-title":"Effect of Chinese herbs on immunoglobulin A nephropathy: a randomized controlled trial","volume":"33","author":"Wei","year":"2013","journal-title":"Journal of Traditional Chinese Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1046\/j.1523-1755.2000.00432.x","article-title":"ACEI\/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis","volume":"58","author":"Woo","year":"2000","journal-title":"Kidney international"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0144|cit144","first-page":"A21","article-title":"High dose ARB and ACE gene polymorphism in IgA nephritis [abstract no: 025]","volume":"13","author":"Woo","year":"2008","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CNP71617","article-title":"Beneficial effects of high-dose losartan in IgA nephritis","volume":"71","author":"Woo","year":"2009","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ki.2008.538","article-title":"Telmisartan is more effective than losartan in reducing proteinuria","volume":"75","author":"Woo","year":"2009","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD003962.pub3-BIB0147|cit147","first-page":"844","article-title":"Clinical study on dan shao tang in treating IgA nephropathy of deficiency of yin with damp-heat symptom","volume":"26","author":"Wu","year":"2003","journal-title":"Zhong Yao Cai [Journal of Chinese Medicinal Materials]"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0148|cit148","first-page":"821A","article-title":"Efficacy and safety of telmisartan, clopidogrelin and leflunomide in patients with IgA nephropathy - a multicentre, prospective, randomized, double-blind, double-dummy controlled clinical trial [abstract no: SA-PO848]","volume":"24","author":"Chen","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0149|cit149","first-page":"389","article-title":"Using the Oxford classification in assessing the therapeutic effects in IgA nephropathy: a secondary analysis from a randomized clinical trial [abstract no: TH-PO1036]","volume":"29","author":"Duan","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"i175","DOI":"10.1093\/ndt\/gft113","article-title":"Efficacy and safety of telmisartan, clopidogrelin, and leflunomide in patients with IgA nephropathy - A multicentre, prospective, randomized, double-blind and-dummy controlled clinical trial [abstract no: SP307]","volume":"28","author":"Wu","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"16","key":"10.1002\/14651858.CD003962.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.4103\/0366-6999.187848","article-title":"Efficacy of leflunomide, telmisartan, and clopidogrel for immunoglobulin A nephropathy: a randomized controlled trial","volume":"129","author":"Wu","year":"2016","journal-title":"Chinese Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11255-019-02329-5","article-title":"Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria","volume":"52","author":"Xiaowei","year":"2020","journal-title":"International Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/0886022X.2015.1128251","article-title":"The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial","volume":"38","author":"Yang","year":"2016","journal-title":"Renal Failure"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/nep.12177","article-title":"Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study","volume":"19","author":"Ye","year":"2014","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0155|cit155","first-page":"503","article-title":"A prospective controlled study of sairei-to in childhood IgA nephropathy with focal\/minimal mesangial proliferation. Japanese Pediatric IgA Nephropathy Treatment Study Group","volume":"39","author":"Yoshikawa","year":"1997","journal-title":"Nippon Jinzo Gakkiai Shi [Japanese Journal of Nephrology]"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0254-6272(11)60024-1","article-title":"The short-term therapeutic effects of TCM for IgA nephropathy in children","volume":"31","author":"Zhou","year":"2011","journal-title":"Journal of Traditional Chinese Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0157|cit157","first-page":"48A","article-title":"Reduction of proteinuria observed in response to high dose ACE inhibition and Omega-3 fatty acids in pts with IgA nephropathy. Report from the second North American IgA nephropathy trial [abstract no: SA-FC059]","volume":"18","author":"Hogg","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0158|cit158","first-page":"523","article-title":"Dose-dependency of the effect of Omega-3 fatty acids (O3FA) on proteinuria in patients with IgA nephropathy: report from the 2nd North American IgA nephropathy trial [abstract no: F-PO860]","volume":"16","author":"Hogg","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2215\/CJN.02300606","article-title":"Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2369-5-3","article-title":"A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]","volume":"5","author":"Hogg","year":"2004","journal-title":"BMC Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0161|cit161","first-page":"567","article-title":"Preliminary report from the second North American IgA nephropathy (IgAN) trial [abstract no: F-PO1098]","volume":"17","author":"Hogg","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0162|cit162","doi-asserted-by":"crossref","unstructured":"Hogg RJ SouthWest Pediatric Nephrology Study Group A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy: study protocol Personal communication 2003","DOI":"10.1186\/1471-2369-5-3"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","article-title":"Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies","volume":"63","author":"Campbell","year":"2003","journal-title":"Kidney International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0164|cit164","first-page":"82A","article-title":"ACE inhibitors (ACEi), angiotensin II antagonists (ATA) or their combination: how to best renoprotect patients with non diabetic chronic nephropathies? [abstract no: A0432]","volume":"12","author":"Perticucci","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0165|cit165","unstructured":"A multi-center, randomized, controlled, double-blind clinical study on the treatment of Chronic kidney disease with Kidney-Yang deficiency syndrome by Wenshenyang prescription https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2000039644"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0166|cit166","first-page":"136","article-title":"One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study","volume":"18","author":"Dal Canton","year":"2005","journal-title":"Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0167|cit167","first-page":"493","article-title":"Prospective controlled therapeutic trial with diaminodiphenylsulfone-dapsone (DDS) in primitive IGA nephropathy (IgAN) [abstract]","volume":"26","author":"Deteix","year":"1984","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0168|cit168","unstructured":"A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapy in preventing the evolution of proliferative lesions assessed by renal biopsy in patients with extracapillary glomerulonephritis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015-003884-12-IT"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0169|cit169","unstructured":"A clinical study to assess efficacy and safety of the human Anti-CD38 Antibody Felzartamab in IgA Nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-005054-19-DE CN-02329124"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0170|cit170","unstructured":"Efficiency of L-carnitine-containing peritoneal dialysis solutions for diurnal exchanges in CAPD patients with ESRD on glucose and lipid metabolisms. Randomized, parallel study compared versus a standard glucose solution 1.5 or 2.5 www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-005298-23"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004872-200201000-00018","article-title":"Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade","volume":"20","author":"Ferrari","year":"2002","journal-title":"Journal of Hypertension"},{"issue":"Sept","key":"10.1002\/14651858.CD003962.pub3-BIB0172|cit172","first-page":"90","article-title":"Additive antiproteinuric effect of combined ace-inhibition and angiotensin II receptor blockade [abstract no: A0491]","volume":"11","author":"Marti","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.ajkd.2004.04.030","article-title":"Can young adult patients with proteinuric IgA nephropathy perform physical exercise?","volume":"44","author":"Fuiano","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0174|cit174","first-page":"209","article-title":"Post-exercise proteinuria in patients (pts) with IgA nephropathy in baseline conditions and after treatment with ramipril (r) [abstract]","volume":"17","author":"Mancuso","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003962.pub3-BIB0175|cit175","first-page":"104A","article-title":"Comparison of immunosuppressive therapy (IST), ace inhibitor (ACEi), and AT1 receptor antagonist (AIIA) in the treatment of IgA nephropathy (IgAN) [abstract no: A0535]","volume":"10","author":"Ihm","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003962.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"iii235","DOI":"10.1093\/ndt\/gfx147.SP365","article-title":"Comparison of the efficacy of denosumab and alendronate in glucocorticoid-induced osteoporosis [abstract no: SP365]","volume":"32","author":"Iseri","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"e0193846","DOI":"10.1371\/journal.pone.0193846","article-title":"The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial","volume":"13","author":"Iseri","year":"2018","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003962.pub3-BIB0178|cit178","first-page":"332A","article-title":"Long term prognosis of severe childhood IgA nephropathy showing diffuse mesangial proliferation [abstract no: TH-PO983]","volume":"19","author":"Kamei","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0179|cit179","first-page":"47A","article-title":"Effect of peroxisome proliferator-activated receptor-gamma (PPAR-g) on inflammatory markers and renal outcome in IgA nephropathy (IgAN) [abstract no: SA-FC058]","volume":"18","author":"Kanjanabuch","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s101570300006","article-title":"A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial","volume":"7","author":"Kanno","year":"2003","journal-title":"Clinical & Experimental Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2215\/CJN.01110905","article-title":"Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors","volume":"1","author":"Kanno","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0182|cit182","first-page":"111","article-title":"Combination treatment of angiotensin II receptor antagonist and ACE inhibitor protects against renal insufficient in non-diabetic kidney disease","volume":"37","author":"Kerst","year":"2003","journal-title":"Geneesmiddelenbulletin"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0183|cit183","first-page":"71","article-title":"Renoprotective effect of the combined use of steroid and angiotensin II receptor blocker in IgA Nephropathy","volume":"24","author":"Kim","year":"2005","journal-title":"Korean Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0184|cit184","first-page":"539","article-title":"Effect of combined treatment of steroid and angiotensin II receptor blocker (ARB) in proteinuric IgA nephropathy","volume":"22","author":"Lee","year":"2003","journal-title":"Korean Journal of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0185|cit185","first-page":"A16","article-title":"Relationship of impairment of the renin-angiotensin system and sodium sensitivity of blood pressure in immunoglobulin A (IgA) nephropathy [abstract no: FC2-04]","volume":"8","author":"Konishi","year":"2003","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1291\/hypres.27.7","article-title":"Blunted response of the renin-angiotensin system and nitric oxide synthesis related to sodium sensitivity in immunoglobulin A nephropathy","volume":"27","author":"Konishi","year":"2004","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/HYPERTENSIONAHA.110.166843","article-title":"Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy","volume":"58","author":"Konishi","year":"2011","journal-title":"Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.HYP.38.1.81","article-title":"Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin A nephropathy","volume":"38","author":"Konishi","year":"2001","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000167463","article-title":"Diclofenac, a nonsteroidal anti-inflammatory drug, decreases proteinuria in some glomerular diseases: a controlled study","volume":"7","author":"Laurent","year":"1987","journal-title":"American Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0190|cit190","first-page":"71","article-title":"Renoprotective effect of the combined use of steroid and angiotensin II receptor blocker in IgA Nephropathy","volume":"24","author":"Kim","year":"2005","journal-title":"Korean Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0191|cit191","first-page":"539","article-title":"Effect of combined treatment of steroid and angiotensin II receptor blocker (ARB) in proteinuric IgA nephropathy","volume":"22","author":"Lee","year":"2003","journal-title":"Korean Journal of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0192|cit192","first-page":"7375006","article-title":"Impact of high-flux hemodialysis on chronic inflammation, antioxidant capacity, body temperature, and immune function in patients with chronic renal failure","volume":"2022","author":"Li","year":"2022","journal-title":"Journal of Healthcare Engineering"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0194|cit194","first-page":"57A","article-title":"Addition of steroids to ACE inhibitors is more preferred to patients with IgA nephropathy: a prospective randomized controlled trial [abstract no: SA-FC105]","volume":"18","author":"Lv","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0195|cit195","first-page":"248","article-title":"Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy","volume":"14","author":"Manno","year":"2001","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0196|cit196","unstructured":"Manno C Torres DD Pesce F Rossini M Schena FP Long-term prospective randomized controlled multicentre trial on steroids plus ramipril in proteinuric IgA nephropathy [abstract no: LB-001] American Society of Nephrology (ASN) Renal Week; 2008 Nov 4-9; Philadelphia (PA) 2008"},{"issue":"12","key":"10.1002\/14651858.CD003962.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0198|cit198","unstructured":"Torres D Rossini M Manno C Gesualdo L Grandaliano G Schena FP Steroids plus ramipril versus ramipril alone in the treatment of IgA nephropathy: interim analysis of a prospective, controlled, randomized, multicenter trial [abstract no: MO27] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 222 3"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0199|cit199","first-page":"70","article-title":"Effect of Yishen Tiaojing Recipe on hypogonadism induced by Tripterygium glycosides in women patients with nephropathy","volume":"28","author":"Mao","year":"2008","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Integrated Traditional & Western Medicine]"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0200|cit200","unstructured":"Michail S Konstadinidou I Chelioti H Darema M Marinaki S Hiras T Comparative study of the effects of lisinopril and losartan or their combination in patients with primary glomerulonephritis [abstract] 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17-20; Nice, France 2000 127"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.jhh.1002264","article-title":"Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases","volume":"22","author":"Mimura","year":"2008","journal-title":"Journal of Human Hypertension"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0202|cit202","first-page":"S131","article-title":"Effect of enalapril (E) on the proteinuria (pr) of patients with primary glomerulopathies (PG) [abstract no: P227]","volume":"3","author":"Morales","year":"1997","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0203|cit203","unstructured":"Zhang H Trial of plasma exchange for severe crescentic IgA nephropathy (RESCUE) https:\/\/clinicalTrials.gov\/show\/NCT02647255"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0204|cit204","unstructured":"Rituximab and RASi in Patients With IgAN (RITA) https:\/\/clinicaltrials.gov\/show\/NCT04525729"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0205|cit205","unstructured":"SodiUm Restriction by Behavioral Intevention (SURBI) https:\/\/clinicaltrials.gov\/show\/NCT04805047"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0206|cit206","unstructured":"A study of telitacicept for injection (RC18) iN subjects with Ig A nephropathy https:\/\/clinicaltrials.gov\/show\/NCT04905212"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0207|cit207","unstructured":"Clinical trial to assess efficacy and safety of the human anti-cd38 antibody felzartamab (MOR202) in IgA nephropathy (IGNAZ) https:\/\/clinicaltrials.gov\/show\/NCT05065970"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0208|cit208","unstructured":"Atacicept in subjects With IgA nephropathy (ORIGIN 3) https:\/\/clinicaltrials.gov\/show\/NCT04716231"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00774-013-0485-2","article-title":"Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis","volume":"32","author":"Inoue","year":"2014","journal-title":"Journal of Bone & Mineral Metabolism"},{"issue":"Sept","key":"10.1002\/14651858.CD003962.pub3-BIB0210|cit210","first-page":"76A","article-title":"Urinary EGF\/MCP-1 ratio is a prognostic marker in IgA nephropathy (IgAN). A prospective randomized clinical trial [abstract no: A0414]","volume":"11","author":"Schena","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0211|cit211","unstructured":"A phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of sibeprenlimab administered subcutaneously in subjects with immunoglobulin A nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=SLCTR\/2022\/013"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMc1600141","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"374","author":"Ayoub","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.kint.2020.05.033","article-title":"Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial","volume":"98","author":"Cheung","year":"2020","journal-title":"Kidney international"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0214|cit214","first-page":"284","article-title":"Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol","volume":"21","author":"Eitner","year":"2008","journal-title":"Journal of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0215|cit215","first-page":"B4","article-title":"Corticosteroid monotherapy versus combined immunosuppression in IgA nephropathy: insights from the STOP-IgAN trial [abstract no: SA-PO1097]","volume":"26","author":"Floege","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0216|cit216","unstructured":"Floege J Rauen T Eitner F Fitzner C Sommerer C Zeier M Supportive versus immunosuppressive therapy for progressive IgA nephropathy (STOP-IGAN): a randomized, controlled, open-label multicenter trial [abstract] 52nd Congress ERA-EDTA; 2015 May 28-31; London, UK 2015"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0217|cit217","unstructured":"Floege J Rauen T Eitner F Moldoveanu Z Fitzner C Mladkova N Galactose-deficient IgA1 levels predict renal outcome in the STOP-IgAN trial cohort [abstract no: 3409] ERA-EDTA News 2017"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0218|cit218","first-page":"992","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"374","author":"Floege","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0219|cit219","first-page":"14A","article-title":"The MEST kidney biopsy score predicts renal outcome in STOP-IgAN trial patients - a post-hoc study [abstract no: TH-OR057]","volume":"27","author":"Floege","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0220|cit220","unstructured":"Floege J Wied S Fitzner C Eitner F Sommerer C Zeier MG Intensive supportive care plus immunosuppression in IgA nephropathy: long-term renal outcomes [abstract no: TH-PO1208] www.asn-online.org\/education\/kidneyweek\/2019\/program-abstract.aspx?controlId=3261159 2019"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.ekir.2019.05.416","article-title":"Dual blockade of the renin-angiotensin system in patients with IgA nephropathy - insights from the STOP-IGAN Trial [abstract no: SUN-021]","volume":"4","author":"Lennartz","year":"2019","journal-title":"Kidney International Reports"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0222|cit222","first-page":"S165","article-title":"Dual blockade of the renin-angiotensin system in patients with IgA nephropathy [abstract no: SAT-395]","volume":"5","author":"Lennartz","year":"2020","journal-title":"KI Reports"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40620-020-00836-8","article-title":"Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy","volume":"33","author":"Lennartz","year":"2020","journal-title":"Journal of Nephrology"},{"issue":"23","key":"10.1002\/14651858.CD003962.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0226|cit226","first-page":"141","article-title":"Dual blockade of the renin-angiotensin system in patients with IgA nephropathy-insights from the Stop-IgAN Trial [abstract]","volume":"4","author":"Rauen","year":"2018","journal-title":"Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMc1600141","article-title":"Intensive supportive care plus Immunosuppression in IgA nephropathy","volume":"374","author":"Robert","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD003962.pub3-BIB0229|cit229","first-page":"992","article-title":"Intensive supportive care plus Immunosuppression in IgA nephropathy","volume":"374","author":"Schena","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12882-018-1128-6","article-title":"Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)","volume":"19","author":"Schimpf","year":"2018","journal-title":"BMC Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0231|cit231","first-page":"229","article-title":"Difficult nephropathies: a multicenter randomized trial on the treatment [abstract]","volume":"12","author":"Sulimani","year":"2001","journal-title":"Saudi Journal of Kidney Diseases and Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0232|cit232","first-page":"S236","article-title":"Efficacy and safety of iptacopan in IgA nephropathy: results of a randomized double-blind placebo-controlled phase 2 study at 6 months [abstract no: POS-546]","volume":"7","author":"Barratt","year":"2022","journal-title":"KI Reports"},{"issue":"Suppl 256","key":"10.1002\/14651858.CD003962.pub3-BIB0233|cit233","first-page":"2S","article-title":"Interim analysis of a Phase 2 dose ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy","volume":"151","author":"Meier","year":"2021","journal-title":"Swiss Medical Weekly"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003962.pub3-BIB0234|cit234","first-page":"iii142","article-title":"A novel oral complement alternative pathway factor B inhibitor for the treatment of glomerular disease [abstract no: LNP023]","volume":"35","author":"Webb","year":"2020","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD003962.pub3-BIB0235|cit235","first-page":"932","article-title":"Does L-arginine alter proteinuria and renal haemodynamics in patients with chronic glomerulonephritis and hypertension? [abstract]","volume":"9","author":"Wolf","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0236|cit236","first-page":"S42","article-title":"Does L-arginine alter proteinuria and renal hemodynamics in patients with chronic glomerulonephritis and hypertension?","volume":"43 Suppl 1","author":"Wolf","year":"1995","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/PL00005832","article-title":"Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis","volume":"66","author":"Yonemura","year":"2000","journal-title":"Calcified Tissue International"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0238|cit238","first-page":"C208","article-title":"Prospective multicenter controlled therapeutic trial in IgA nephropathy in Japanese children: a preliminary report [abstract no: S-I-2]","volume":"6","author":"Ito","year":"1992","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"Kamei","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1681\/ASN.V101101","article-title":"A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group","volume":"10","author":"Yoshikawa","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/14.5.1097","article-title":"Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?","volume":"14","author":"Yoshikawa","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD003962.pub3-BIB0242|cit242","first-page":"C31","article-title":"Corticosteroids and immunosuppressive drugs [abstract no: S8.2]","volume":"16","author":"Yoshikawa","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0243|cit243","first-page":"1401","article-title":"A controlled trial of prednisolone (P), azathioprine (A), heparin-warfarin (H-W) and dipyridamole (D) in newly diagnosed severe childhood IgA nephropathy (IGAN) [abstract no: A0779]","volume":"7","author":"Yoshikawa","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2215\/CJN.01120905","article-title":"Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial","volume":"1","author":"Yoshikawa","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Sept","key":"10.1002\/14651858.CD003962.pub3-BIB0245|cit245","first-page":"79A","article-title":"Prednisolone therapy versus combined therapy with prednisolone, azathioprine, warfarin and dipyridamole for newly diagnosed severe childhood IgA nephropathy: a controlled trial by the Japanese Pediatric IgA Nephropathy Treatment study group [abstract no: A0430]","volume":"11","author":"Yoshikawa","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0246|cit246","first-page":"C57","article-title":"Treatment of IGA nephropathy in children [abstract no: FCP04]","volume":"19","author":"Yoshikawa","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD003962.pub3-BIB0247|cit247","first-page":"337A","article-title":"Efficacy and safety of leflunomide in the treatment of IgA nephropathy: preliminary results from a randomized, corticosteroid controlled, multi-center clinical trial [abstract no: SA-PO168]","volume":"15","author":"Zhang","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003962.pub3-BIB0248|cit248","first-page":"567A","article-title":"Efficacy and safety of leflunomide in the treatment of IgA nephropathy: a perspective, corticosteroid controlled, multi-center clinical trial [abstract no: F-PO1097]","volume":"17","author":"Zhang","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0249|cit249","unstructured":"Koyama A Narita M Tojo S Therapeutic effects of dipyridamole on primary glomerulonephritis [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 12"},{"issue":"1032","key":"10.1002\/14651858.CD003962.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/pgmj.2011.118059","article-title":"Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease","volume":"87","author":"Lee","year":"2011","journal-title":"Postgraduate Medical Journal"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0251|cit251","unstructured":"Phase 2 study of VIS649 for IgA nephropathy https:\/\/clinicaltrials.gov\/show\/NCT04287985"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0252|cit252","unstructured":"A study of RC18 administered subcutaneously to subjects with IgA (Immunoglobulin A) nephropathy https:\/\/clinicaltrials.gov\/show\/NCT04291781"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0253|cit253","unstructured":"Study of efficacy and safety of LNP023 in primary IgA nephropathy patients https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-001049-38-FI"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0254|cit254","unstructured":"Study of efficacy and safety of LNP023 in primary IgA nephropathy Patients (APPLAUSE-IgAN) https:\/\/clinicaltrials.gov\/show\/NCT04578834"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0255|cit255","unstructured":"A study to evaluate the safety, tolerability and pharmacokinetics pharmacodynamics of SHR-2010 by intravenously\/subcutaneously in healthy subject https:\/\/clinicaltrials.gov\/show\/NCT05398510"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0256|cit256","first-page":"1345","article-title":"Short-term and long-term efficacy, safety assessment and independent prognostic risk factors of hydroxychloroquine in the treatment of IgA nephropathy","volume":"36","author":"Yu","year":"2020","journal-title":"Acta Medica Mediterranea"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0257|cit257","first-page":"508","article-title":"ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study","volume":"19","author":"Pozzi","year":"2006","journal-title":"Journal of Nephrology"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD003962.pub3-BIB0258|cit258","first-page":"77","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of atrasentan in patients with IgA nephropathy (The ALIGN Study) [abstract]","volume":"7","author":"Heerspink","year":"2021","journal-title":"Kidney Diseases"},{"issue":"SUPPL 1","key":"10.1002\/14651858.CD003962.pub3-BIB0259|cit259","first-page":"i194","article-title":"A phase 3, randomized, double-blind, placebo controlled study of atrasentan in patients with IgA nephropathy (the ALIGN study) [abstract no: MO230]","volume":"36","author":"Heerspink","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0260|cit260","first-page":"S229","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of atrasentan in patients with IgA nephropathy (The ALIGN Study) [abstract no: POS-527]","volume":"7","author":"Lambers Heerspink","year":"2022","journal-title":"KI Reports"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003962.pub3-BIB0261|cit261","first-page":"S164","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of atrasentan in patients with IgA nephropathy (the ALIGN Study) [abstract no: Pos-380]","volume":"6","author":"Lambers Heerspink","year":"2021","journal-title":"KI Reports"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"i397","DOI":"10.1093\/ndt\/gfad063c_4341","article-title":"ASSIST study design: a randomized, double-blind, placebo-controlled, crossover study of atrasentan in patients with IgA nephropathy (IGAN) on SGLT2I [abstract no: 4341]","volume":"38","author":"Heerspink","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0263|cit263","unstructured":"Randomized, double-blind, placebo-controlled, crossover study of atrasentan in subjects with IgA nephropathy (ASSIST) https:\/\/clinicaltrials.gov\/show\/NCT05834738 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0264|cit264","unstructured":"Ryu DR Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 (BEST-IgAN-1) https:\/\/clinicaltrials.gov\/study\/NCT03357653"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0265|cit265","first-page":"444","article-title":"Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial","volume":"23","author":"Chen","year":"2022","journal-title":"Trials [Electronic Resource]"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0266|cit266","unstructured":"A multicentre, randomized, controlled trial of rituximab in treatment of primary IgA nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2000036468"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0267|cit267","unstructured":"A multicenter, randomized, controlled clinical trial of Hydroxychloroquine or new Tripterygium compound in the treatment of IgA nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100045306"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0268|cit268","unstructured":"A single-case randomized controlled study of Huaiqihuang granules in treatment of proteinuria in IgA nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100049833"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0269|cit269","unstructured":"A clinical study of traditional Chinese medicine combined with Western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3 https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200062663 2022"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0270|cit270","unstructured":"Clinical study of valsartan combined with Chuanhuang No.1 Prescription in the treatment of CKD3 primary IgA nephropathy (IgAN) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200063885 2022"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0271|cit271","unstructured":"Prednisone combined with ARB in the treatment of IgAN with crescentic lesions: a perspective, multi-center randomized controlled trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200064055 2022"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0272|cit272","unstructured":"A multicenter, prospective, randomized controlled clinical study of Yishenhuashui granule in the treatment of IgAN https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200065760 2022"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0273|cit273","unstructured":"Prospective randomized controlled study of Qufeng Bushen Huoluo recipe in the treatment of hematuria in IgA Nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200066983 2022"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0274|cit274","unstructured":"Efficacy and safety of dapagliflozin in adults with primary IgA nephropathy: a single-center, prospective, open, randomized controlled trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300067263 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0275|cit275","unstructured":"Development and application of traditional Chinese medicine tea bag for IgA nephropathy prevention and treatment based on the theory of ''pharyngokidney correlation'' https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300070499 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0276|cit276","unstructured":"To explore the mechanism of Jianpi Heluo Formula in treating IgA nephropathy from intestinal microflora -immune system-IgA nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300070929 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0277|cit277","unstructured":"Clinical and mechanism study of Xuanfei Jingshui decoction in the treatment of IgA nephropathy based on intestinal flora https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300073242 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0278|cit278","unstructured":"Safety and efficacy of fecal microbiota transplantation in the treatment of IgA nephropathy: a randomized controlled clinical trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300075319 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0279|cit279","unstructured":"A single-center randomized crossover controlled trial to evaluate the efficacy and safety of azisartan in the treatment of proteinuria and renal function in non-dialytic hypertensive patients with IgA nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2300076082 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1681\/ASN.20213210S1509d","article-title":"Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy (IgAN) [abstract no: PO1634]","volume":"32","author":"Schena","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/ckj\/sfab263","article-title":"Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy","volume":"15","author":"Schena","year":"2022","journal-title":"Clinical Kidney Journal"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0282|cit282","unstructured":"To know the effect of capsule budesonide on protein leak from kidney and filtration function of the kidney in persons having IgA nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/02\/031480"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0283|cit283","unstructured":"A study comparing oral hydroxychloroquine and supportive treatment with supportive treatment alone for management of IgA nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2021\/07\/034929"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0284|cit284","unstructured":"A study to look at the effect and how safe drug VIS649 is in patients with kidney disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-002531-29-GB"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0285|cit285","unstructured":"Evaluation of the effect of probiotic supplementation on the proteinuria https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20190415043279N11"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0286|cit286","unstructured":"Influence of IgA Nephropathy? Prescription on serum Gd-IgA1 and BAFF level for patients with IgA nephropathy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ITMCTR2200005824 2022"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0287|cit287","first-page":"170","article-title":"Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial","volume":"18","author":"Li","year":"2017","journal-title":"Trials [Electronic Resource]"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"153231","DOI":"10.1016\/j.phymed.2020.153231","article-title":"Efficacy and safety of abelmoschus manihot for IgA nephropathy: a multicenter randomized clinical trial","volume":"76","author":"Li","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0289|cit289","unstructured":"Deng Y Validity and security of Reh-acteoside therapy for patients of IgA nephropathy https:\/\/clinicalTrials.gov\/show\/NCT02662283"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0290|cit290","unstructured":"Gao R Hydroxychloroquine sulfate alleviates persistent proteinuria in IgA nephropathy (HCQIgAN) https:\/\/clinicalTrials.gov\/show\/NCT02765594"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0291|cit291","unstructured":"Atrasentan in patients With IgA Nephropathy (ALIGN) https:\/\/clinicaltrials.gov\/show\/NCT04573478"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0292|cit292","unstructured":"A study to evaluate the efficacy and safety of HR19042 capsules in the treatment of primary IgA nephropathy https:\/\/clinicaltrials.gov\/show\/NCT05016323"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0293|cit293","unstructured":"Study of ARO-C3 in adult healthy volunteers and patients with complement-mediated renal disease https:\/\/clinicaltrials.gov\/show\/NCT05083364"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0294|cit294","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.ekir.2023.02.124","article-title":"WCN23-0141 A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF ALXN2050, A COMPLEMENT FACTOR D INHIBITOR, IN IMMUNOGLOBULIN A NEPHROPATHY OR PROLIFERATIVE LUPUS NEPHRITIS (LN)","volume":"8","author":"Bapat","year":"2023","journal-title":"Kidney international reports"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0295|cit295","unstructured":"Study of ALXN2050 in proliferative lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN) https:\/\/clinicaltrials.gov\/show\/NCT05097989 CN-02335962"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0296|cit296","unstructured":"Jinghua Weikang capsule containing quadruple therapy for IgAN with Helicobacter pylori infection https:\/\/clinicaltrials.gov\/show\/NCT05320133 CN-02392342"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0297|cit297","unstructured":"A study to evaluate the efficacy and safety of SC0062 in the treatment of chronic kidney disease https:\/\/clinicaltrials.gov\/show\/NCT05687890 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0298|cit298","unstructured":"Clinical study of CM338 in the treatment of immunoglobulin A nephropathy https:\/\/clinicaltrials.gov\/show\/NCT05775042 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0299|cit299","unstructured":"A study to evaluate the efficacy and safety of RO7434656 in participants with primary immunoglobulin A (IgA) nephropathy at high risk of progression (IMAGINATION) https:\/\/clinicaltrials.gov\/show\/NCT05797610 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0300|cit300","unstructured":"A study of telitacicept in patients with primary IgA nephropathy https:\/\/clinicaltrials.gov\/show\/NCT05799287 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0301|cit301","unstructured":"Efficacy and safety of SHR-2010 injection in the treatment of primary IgA nephropathy https:\/\/clinicaltrials.gov\/show\/NCT05847920 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0302|cit302","unstructured":"A study of BION-1301 in adults With IgA nephropathy https:\/\/clinicaltrials.gov\/show\/NCT05852938 2023"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0303|cit303","unstructured":"A trial of HRS-5965 tablets in primary IgA nephropathy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06137768 2023"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003962.pub3-BIB0304|cit304","doi-asserted-by":"publisher","first-page":"i23-4","DOI":"10.1093\/ndt\/gfad063a_4057","article-title":"Superior proteinuria reduction with sparsentan in immunoglobulin A nephropathy (IGAN): a PROTECT study interim analysis [abstract no: 4057]","volume":"38","author":"Barratt","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0305|cit305","first-page":"142","article-title":"Protect in immunoglobulin a nephropathy (IgAN): Study design of a phase 3, randomized, double- blind, international, active-controlled study of the efficacy and safety of sparsentan [abstract]","volume":"4","author":"Barratt","year":"2018","journal-title":"Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD003962.pub3-BIB0306|cit306","first-page":"1633","article-title":"Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT Trial)","volume":"4","author":"Barratt","year":"2019","journal-title":"KI Reports"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0307|cit307","first-page":"1043","article-title":"IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study","volume":"8","author":"Barratt","year":"2023","journal-title":"KI Reports"},{"issue":"10388","key":"10.1002\/14651858.CD003962.pub3-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0309|cit309","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1053\/j.ajkd.2023.01.331","article-title":"Proteinuria reduction with sparsentan in immunoglobulin A nephropathy (IGAN): PROTECT study interim results [abstract no: 329]","volume":"81","author":"Radhakrishnan","year":"2023","journal-title":"American Journal of Kidney Diseases"},{"issue":"10417","key":"10.1002\/14651858.CD003962.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003962.pub3-BIB0311|cit311","first-page":"i142","article-title":"Baseline characteristics of adults enrolled in the ongoing phase 3 randomized, double-blind, active-control trial of sparsentan for the treatment of immunoglobulin A nephropathy (PROTECT) [abstract no: MO209]","volume":"37","author":"Wong","year":"2022","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0312|cit312","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.1016\/j.ekir.2023.02.633","article-title":"WCN23-1181 Immunoglobulin A nephropathy (IGAN) patient baseline characteristics in Asian versus non-Asian regions in the sparsentan PROTECT study","volume":"8","author":"Wong","year":"2023","journal-title":"KI Reports"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0313|cit313","doi-asserted-by":"publisher","first-page":"S126-7","DOI":"10.1016\/j.ekir.2023.02.286","article-title":"WCN23-1087 Sparsentan reduces proteinuria in patients with immunoglobulin A nephropathy (IGAN): interim results of the PROTECT study","volume":"8","author":"Wong","year":"2023","journal-title":"KI Reports"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0314|cit314","unstructured":"Atacicept in subjects with IgA Nephropathy: a Phase 2b\/3, Multi-part, randomized, double-blinded, placebo- controlled trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=SLCTR\/2023\/021 2023"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0315|cit315","first-page":"31","article-title":"Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial","volume":"21","author":"Li","year":"2020","journal-title":"Trials [Electronic Resource]"},{"issue":"7","key":"10.1002\/14651858.CD003962.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy [Erratum in: JAMA Intern Med. 2019 Jul 1;179(7):1007]","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD003962.pub3-BIB0317|cit317","first-page":"694","article-title":"Intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"Journal d Urologie et de Nephrologie"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2019.01.047","article-title":"Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease","volume":"95","author":"Carter","year":"2019","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattan","year":"2009","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD003962.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/nep.12538","article-title":"Long-term outcomes for primary glomerulonephritis: New Zealand Glomerulonephritis Study","volume":"20","author":"Chembo","year":"2015","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000100431","article-title":"Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy","volume":"27","author":"Chen","year":"2007","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1742-1241.2009.02038.x","article-title":"ACEI\/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials","volume":"63","author":"Cheng","year":"2009","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0323|cit323","unstructured":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials https:\/\/www.equator-network.org\/reporting-guidelines\/consort\/ 2010"},{"issue":"245","key":"10.1002\/14651858.CD003962.pub3-BIB0324|cit324","first-page":"709","article-title":"The commonest glomerulonephritis in the world: IgA nephropathy","volume":"64","author":"D'Amico","year":"1987","journal-title":"Quarterly Journal of Medicine"},{"issue":"7305","key":"10.1002\/14651858.CD003962.pub3-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","article-title":"Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests","volume":"323","author":"Deeks","year":"2001","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11255-016-1432-7","article-title":"Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis","volume":"49","author":"Duan","year":"2017","journal-title":"International Urology & Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0328|cit328","first-page":"1450","article-title":"Analyzing antibody activity in IgA nephropathy","volume":"119","author":"Glassock","year":"2009","journal-title":"Journal of Clinical Investigation"},{"issue":"7650","key":"10.1002\/14651858.CD003962.pub3-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in Ig A nephropathy","volume":"28","author":"Haas","year":"2017","journal-title":"Journal of American Society of Nephrology"},{"issue":"7414","key":"10.1002\/14651858.CD003962.pub3-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0333|cit333","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate endpoint in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inkler","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0336|cit336","first-page":"53","article-title":"Progress in the pathogenesis of IgA nephropathy","volume":"29","author":"Julian","year":"1999","journal-title":"Advances in Nephrology From the Necker Hospital"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"118","DOI":"10.12771\/emj.2016.39.4.118","article-title":"A patient with IgA nephropathy: 5 years after complete remission of minimal change nephrotic syndrome","volume":"39","author":"Kim","year":"2016","journal-title":"EWHA Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD003962.pub3-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Neprhology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40620-020-00836-8","article-title":"Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy","volume":"33","author":"Lennartz","year":"2020","journal-title":"Journal of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003962.pub3-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"Journal of American Society of Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000422410","article-title":"Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy","volume":"104","author":"Mestecky","year":"1993","journal-title":"Contributions to Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003962.pub3-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"e89707","DOI":"10.1371\/journal.pone.0089707","article-title":"Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy","volume":"9","author":"Nakata","year":"2014","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0344|cit344","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003965.pub3","article-title":"Immunosuppressive agents for treating IgA nephropathy","author":"Natale","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1046\/j.1523-1755.1999.07008.x","article-title":"Management of IgA nephropathy: evidence-based recommendations","volume":"70","author":"Nolin","year":"1999","journal-title":"Kidney International - Supplement"},{"issue":"9638","key":"10.1002\/14651858.CD003962.pub3-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD003962.pub3-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Teo","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD003962.pub3-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"Journal American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000188480","article-title":"Immunomodulation with low-dose immunoglobulins for moderate IgA nephropathy and Henoch-Schonlein Purpura. Preliminary results of a prospective uncontrolled trial","volume":"69","author":"Rostoker","year":"1995","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0002-9343(01)00684-2","article-title":"Immunoglobulin A nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists","volume":"110","author":"Schena","year":"2001","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0351|cit351","volume-title":"Epidemiology and Ancestral Difference. Recent Advances in IgA Nephropathy","volume":"12","author":"Schena","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Seminars in Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-14-72","article-title":"Coagulation activation, depletion of platelet granules and endothelial integrity in case of uraemia and haemodialysis treatment","volume":"14","author":"Schoorl","year":"2013","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0354|cit354","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0355|cit355","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10157-019-01700-1","article-title":"New strategies and perspectives on managing IgA nephropathy","volume":"23","author":"Selvaskandan","year":"2019","journal-title":"Clinical & Experimental Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003962.pub3-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","article-title":"Incidence of latent mesangial IgA deposition in renal allograft donors in Japan","volume":"63","author":"Suzuki","year":"2003","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD003962.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1755-1536-3-7","article-title":"The role of renin angiotensin system inhibition in kidney repair","volume":"3","author":"Meer","year":"2010","journal-title":"Fibrogenesis & Tissue Repair"},{"issue":"5","key":"10.1002\/14651858.CD003962.pub3-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD003962.pub3-BIB0361|cit361","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003962.pub2","article-title":"Non-immunosuppressive treatment for IgA nephropathy","author":"Reid","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003962.pub3-BIB0362|cit362","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003962","article-title":"Non-immunosuppressive treatment for IgA nephropathy","author":"Samuels","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T15:06:05Z","timestamp":1735743965000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003962.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":362,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003962.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}